Table 3.
DFS, OS, and Local recurrence rate of the studies included with solitary CRLM.
| References | Modality | DFS in months/5 y DFS in % | Median OS in months | 5 y OS in % | Local recurrence rate in % | ||||
|---|---|---|---|---|---|---|---|---|---|
| Aliyev et al. (26) | RFA | Not reported | ns | 22 | ns | 47 | ns | 18 | Significant |
| Resection | Not reported | 25 | 57 | 4 | |||||
| Aloia et al. (23) | RFA | 0 | Significant | 47 | Significant | 27 | Significant | 37 | Significant |
| Resection | 50 | 126 | 71 | 5 | |||||
| Hur et al. (28) | RFA | Not reported | Not reported | 25.5 | Significant | 28 | ns | ||
| Resection | Not reported | Not reported | 50.1 | 9.5 | |||||
| Ko et al. (38) | RFA | 17.6 | ns | Not reported | 37.8 | ns | na | ||
| Resection | 22.2 | Not reported | 66.7 | na | |||||
| Lee et al. (37) | RFA | 21.1 | ns | 40 | ns | 48.5 | ns | 29.7 | Significant |
| Resection | 23.7 | 44.7 | 65.7 | 6.9 | |||||
| Oshowo et al. (24) | RFA | Not reported | 34 | ns | 52.6 | ns | Not reported | ||
| Resection | Not reported | 41 | 55.5 | 3 y OS | Not reported | ||||
| White et al. (34) | RFA | 17 | Significant | 31 | Significant | Not reported | 55 | Not reported | |
| Resection | 68 | PFS | 80 | Not reported | 12 | Local disease progression | |||
RFA, Radiofrequency ablation; ns, not significant; DFS, disease free survival; OS, overall survival; y, year; PFS, Progression free survival. The bold represent significant values.